Correlation Between Unicycive Therapeutics and Sigilon Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Sigilon Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Sigilon Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and Sigilon Therapeutics, you can compare the effects of market volatilities on Unicycive Therapeutics and Sigilon Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Sigilon Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Sigilon Therapeutics.

Diversification Opportunities for Unicycive Therapeutics and Sigilon Therapeutics

0.0

Correlation Coefficient

Unicycive Therapeutics  Sigilon Therapeutics

Pay attention - limited upside

The 3 months correlation between Unicycive and Sigilon is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Sigilon Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sigilon Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Sigilon Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sigilon Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Sigilon Therapeutics go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Sigilon Therapeutics

If you would invest (100.00) in Sigilon Therapeutics on December 30, 2024 and sell it today you would earn a total of  100.00  from holding Sigilon Therapeutics or generate -100.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Unicycive Therapeutics  vs.  Sigilon Therapeutics

Unicycive Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Unicycive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Sigilon Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sigilon Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Sigilon Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Unicycive Therapeutics and Sigilon Therapeutics

The main advantage of trading using opposite Unicycive Therapeutics and Sigilon Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Sigilon Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sigilon Therapeutics will offset losses from the drop in Sigilon Therapeutics' long position.

The idea behind Unicycive Therapeutics and Sigilon Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.